Evidence map›Paper›PMID 39579383›Full record

Trial reportMedical physics2025

The TROG 15.01 stereotactic prostate adaptive radiotherapy utilizing kilovoltage intrafraction monitoring (SPARK) clinical trial database.

Chandrima Sengupta, Doan Trang Nguyen, Yifan Li, Emily Hewson, Helen Ball, Ricky O'Brien, Jeremy Booth, John Kipritidis, Thomas Eade, Andrew Kneebone and 18 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02397317 (Stereotactic Prostate Adaptive Radiotherapy Utilising Kilovoltage Intrafraction), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02397317 nacompletednot on this map

Stereotactic Prostate Adaptive Radiotherapy Utilising Kilovoltage Intrafraction

TypeinterventionalSponsorUniversity of SydneyRan2016 to 2020Enrolled49ConditionsProstate CancerArmsMulti-fraction SABR
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Chandrima SenguptaImage X Institute, The University of Syndey, Sydney, Australia.
Doan Trang NguyenImage X Institute, The University of Syndey, Sydney, Australia.
Yifan LiImage X Institute, The University of Syndey, Sydney, Australia.
Emily HewsonImage X Institute, The University of Syndey, Sydney, Australia.
Helen BallImage X Institute, The University of Syndey, Sydney, Australia.
Ricky O'BrienImage X Institute, The University of Syndey, Sydney, Australia.
Jeremy BoothNorther Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia.
John KipritidisNorther Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia.
Thomas EadeNorther Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia.
Andrew KneeboneNorther Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia.
George HrubyNorther Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia.
Regina BromleyNorther Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia.
Peter GreerDepartment of Radiation Oncology, Calvary Mater Newcastle, Newcastle, Australia.
Jarad MartinDepartment of Radiation Oncology, Calvary Mater Newcastle, Newcastle, Australia.
Perry HunterDepartment of Radiation Oncology, Calvary Mater Newcastle, Newcastle, Australia.
Lee WiltonDepartment of Radiation Oncology, Calvary Mater Newcastle, Newcastle, Australia.
Trevor MoodieCrown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia.
Amy HaydenCrown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia.
Sandra TurnerCrown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia.
Nicholas HardcastleDepartment of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, Australia.
Shankar SivaDepartment of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, Australia.
Keen-Hun TaiDepartment of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, Australia.
Sankar ArumugamLiverpool and Macarthur Cancer Therapy Centres, Liverpool Hospital, Liverpool, Australia.
Mark SidhomLiverpool and Macarthur Cancer Therapy Centres, Liverpool Hospital, Liverpool, Australia.
Per PoulsenDepartment of Oncology, Aarhus University Hospital and Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
Val GebskiNHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
Alisha MooreTROG Cancer Research, Waratah, Australia.
Paul KeallImage X Institute, The University of Syndey, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe US National Institutes of Health state that Sharing of clinical trial data has great potential to accelerate scientific progress and ultimately improve public health by generating better evidence on the safety and effectiveness of therapies for patients (https://www.ncbi.nlm.nih.gov/books/NBK285999/ accessed 2024-01-24.). Aligned with this initiative, the Trial Management Committee of the Trans-Tasman Radiation Oncology Group (TROG) 15.01 Stereotactic Prostate Adaptive Radiotherapy utilizing Kilovoltage intrafraction monitoring (KIM) (SPARK) clinical trial supported the public sharing of the clinical trial data. ACQUISITION AND VALIDATION

methodsThe data originate from the TROG 15.01 SPARK clinical trial. The SPARK trial was a phase II prospective multi-institutional clinical trial (NCT02397317). The aim of the SPARK clinical trial was to measure the geometric and dosimetric cancer targeting accuracy achieved with a real-time image-guided radiotherapy technology named KIM for 48 prostate cancer patients treated in 5 treatment sessions. During treatment, real-time tumor translational and rotational motion were determined from x-ray images using the KIM technology. A dose reconstruction method was used to evaluate the dose delivered to the target and organs-at-risk. Patient-reported outcomes and toxicity data were monitored up to 2 years after the completion of the treatment. DATA FORMAT AND USAGE NOTES: The dataset contains planning CT images, treatment plans, structure sets, planned and motion-included dose-volume histograms, intrafraction kilovoltage, and megavoltage projection images, tumor translational and rotational motion determined by KIM, tumor motion ground truth data, the linear accelerator trajectory traces, and patient treatment outcomes. The dataset is publicly hosted by the University of Sydney eScholarship Repository at https://doi.org/10.25910/qg5d-6058. POTENTIAL APPLICATIONS: The 3.6 Tb dataset, with approximately 1 million patient images, could be used for a variety of applications, including the development of real-time image-guided methods, adaptation strategies, tumor, and normal tissue control modeling, and prostate-specific antigen kinetics.

Indexed as

Databases, FactualDose Fractionation, RadiationProstatic NeoplasmsRadiosurgeryHumansMaleRadiotherapy, Image-GuidedIntrafraction tumor motionProstate SABR datasetReal‐time 6DoF prostate motion

Identifiers

PMID39579383
PMCPMC11880642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.